Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
Profitability Metrics
Gross Margin
100.00%
Operating Margin
43.64%
Net Margin
34.71%
Efficiency Metrics
Revenue per Expense Ratio
2.25
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
0.00%
Income Tax Rate
19.98%
EPS
4.9100000000
Balance Sheet Analysis
Current Ratio
0.10
Cash Ratio
0.04
Working Capital
$-33.08B
Debt to Equity
0.39
Debt to Assets
4.55%
Equity Ratio
11.60%
Cash Flow Analysis
Operating Cash Flow Ratio
39.16%
Free Cash Flow Ratio
37.54%
CapEx to Revenue
1.61%
Dividends Paid
$294.81M
Stock Buybacks
$124.26M
Total Shareholder Returns
$419.07M
Cash Position Change
104.28%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 9.90%
Detailed Growth Metrics
Core Performance
Revenue
1.12%
Net Income
34.70%
EPS
31.99%
Operating Income
4.06%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
2.46%
Operating Cash Flow
-26.75%
Free Cash Flow
-28.22%
Balance Sheet Health
Assets
5.15%
Debt
-47.83%
Book Value per Share
5.15%
Inventory
0.00%
Shareholder Returns
Dividends per Share
9.90%
Shares Outstanding
2.58%
Long Term Trends
3Y Revenue/Share
11.45%
5Y Revenue/Share
12.82%
3Y Dividend/Share
1.02%
5Y Dividend/Share
28.44%